Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by lscfaon Jun 10, 2022 12:57pm
165 Views
Post# 34747573

RE:RE:Shares issued

RE:RE:Shares issuedHave seen this abuse of the rules by Reliq Health.    Reliq swore it would not need to do any more financings suggesting the end of dilutiuon.  Instead it issued 10's of millions of options to consultants who exercised them almost immediately. Stealth financing.  



lscfa wrote: Maybe consultants exercising early....

On January 1, 2022, options to purchase up to 4,325,000 common shares of the Company at a price of $0.17 per share for a period of three years were granted to consultants of the Company. 175,000 of these options were exercised during period.    



lscfa wrote:

 

Must be exercise of options. Are employees exercising early because the warrants are worthless upon firing or exercising early to provide funds to co.?
 

 

At Jan 31

236,067,566

Feb Wrts exercised

12,258,960

 

248,326,526

Currently o/s

251,181,526

Difference =

2,855,000

 





<< Previous
Bullboard Posts
Next >>